Status:
RECRUITING
A Study Evaluating TRIV-509 in Atopic Dermatitis
Lead Sponsor:
Triveni Bio
Conditions:
Atopic Dermatitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The goal of this interventional study is to learn if TRIV-509 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-509. Participants will receive 4 ...
Eligibility Criteria
Inclusion
- Has Atopic Dermatitis.
- Has moderate to severe, active and symptomatic AD
Exclusion
- Severe or uncontrolled medical conditions.
- Use of topical treatments, phototherapy, systemic immunosuppressives or immunomodulatory therapies, or immunomodulatory biologics, within stated washout periods.
Key Trial Info
Start Date :
August 26 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT07167758
Start Date
August 26 2025
End Date
June 1 2027
Last Update
December 15 2025
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Triveni Bio Site #11
Fountain Valley, California, United States, 17271
2
Triveni Bio Site #4
San Diego, California, United States, 92123
3
Triveni Bio Site #3
Miami, Florida, United States, 33016
4
Triveni Bio Site #7
Tampa, Florida, United States, 33607